Clinical
Development

Clinigen is continually working to bring medical therapeutics to the patients who need them most.

Our pharmaceutical drug—Proleukin® (aldesleukin)—is the first and only interleukin-2 (IL-2) product approved for use by the US Food and Drug Administration (FDA) as well as other major non-US regulators. Proleukin continues to be an important treatment option for appropriate patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). It is also increasingly being investigated in the cell therapy space, both as:

  • An ex vivo cell-expansion medium
  • In vivo, as an adjunct therapy to tumor-infiltrating lymphocytes (TIL) and other cell therapy modalities









What is now proved was once only imagined.

William Blake








Promising cell therapies

Clinigen is committed to the development of exciting cell therapies. We are actively collaborating with industry and academic partners, scientists, and researchers who are working to bring cellular treatments to people living with cancer, autoimmune diseases, and other medical conditions.

We are also exploring investigational uses of IL-2 across a range of treatment paradigms.